4D Molecular Therapeutics/$FDMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About 4D Molecular Therapeutics
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Ticker
$FDMT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
227
ISIN
US35104E1001
FDMT Metrics
BasicAdvanced
$177M
-
-$3.18
2.86
-
Price and volume
Market cap
$177M
Beta
2.86
52-week high
$28.93
52-week low
$2.24
Average daily volume
433K
Financial strength
Current ratio
12.364
Quick ratio
11.95
Long term debt to equity
3.869
Total debt to equity
5.078
Management effectiveness
Return on assets (TTM)
-22.19%
Return on equity (TTM)
-32.97%
Valuation
Price to revenue (TTM)
9,273.608
Price to book
0.38
Price to tangible book (TTM)
0.38
Price to free cash flow (TTM)
-1.356
Growth
Revenue change (TTM)
-99.89%
Earnings per share change (TTM)
31.41%
3-year revenue growth (CAGR)
-89.00%
3-year earnings per share growth (CAGR)
4.40%
What the Analysts think about FDMT
Analyst ratings (Buy, Hold, Sell) for 4D Molecular Therapeutics stock.
FDMT Financial Performance
Revenues and expenses
FDMT Earnings Performance
Company profitability
FDMT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for 4D Molecular Therapeutics stock?
4D Molecular Therapeutics (FDMT) has a market cap of $177M as of June 06, 2025.
What is the P/E ratio for 4D Molecular Therapeutics stock?
The price to earnings (P/E) ratio for 4D Molecular Therapeutics (FDMT) stock is 0 as of June 06, 2025.
Does 4D Molecular Therapeutics stock pay dividends?
No, 4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next 4D Molecular Therapeutics dividend payment date?
4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders.
What is the beta indicator for 4D Molecular Therapeutics?
4D Molecular Therapeutics (FDMT) has a beta rating of 2.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.